New education platform focuses on diabetes technology training, data management and remote patient monitoring (RPM)

NICE approve Saxenda injections (GLP-1 therapy) for people with pre-diabetes who have BMI of at least 35 kg/m² and high cardiovascular risk. Further details outlined on NICE website:

https://www.nice.org.uk/news/article/nice-recommends-new-treatment-option-for-adults-with-obesity-and-non-diabetic-hyperglycaemia-who-have-a-high-risk-of-cardiovascular-disease

We provide a range of education to people with diabetes to help them make the best use of diabetes technology.

We offer a range of resources for healthcare professionals, including Academy™ - the educational platform for diabetes technology and a series of educational videos featuring experts in the field.

Coming to your inbox on the 18th November - make sure it doesn't get buried under all the other very important emails!

We are due to launch the annual census of Consultants in Diabetes and Endocrinology. This is being done on behalf of ABCD, SfE, Diabetes UK and The Royal College of Physicians London who are also project managing this census.

There has never been a more important time to gather information about how were all working and the impact our jobs have on our lives.

It is vital that all health care professionals understand why cardiac and renal risk require BOTH measurement of urine albumin creatinine ratios AS WELL as eGFR.

Cardiology, Renal and Metabolic (CaReMe) group have produced a very helpful leaflet for people with diabetes on SGLT-2 inhibitors.

SGLT-2 inhibitors are being increasingly used in people with type 2 diabetes to improve diabetes control with the added benefits of weight loss, reduction in BP, reduction in admission from heart failure, reduction in cardiovascular and overall mortality and reduction in renal deterioration.